Scinai Immunotherapeutics (SCNI) Shares Outstanding (Weighted Average) (2014 - 2025)

Scinai Immunotherapeutics has disclosed Shares Outstanding (Weighted Average) across 9 years of filings, most recently posting $9.3 billion for Q4 2025.

• Shares Outstanding (Weighted Average) for Q4 2025 came in at $9.3 billion, up 189.55% year-over-year; the trailing twelve-month figure through Dec 2025 was $9.3 billion (up 189.55% YoY), and the FY2025 annual result was $9.3 billion, up 189.55% from the prior year.
• Shares Outstanding (Weighted Average) came in at $9.3 billion for Q4 2025 at Scinai Immunotherapeutics, up from $1.0 in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $9.3 billion in Q4 2025 to a low of $1.0 in Q2 2025.
• The 5-year median for Shares Outstanding (Weighted Average) is $573.2 million (2021), against an average of $1.4 billion.
• Across the five-year window, Shares Outstanding (Weighted Average) surged 553.34% in 2021 and plunged 100.0% in 2022, its largest moves.
• Scinai Immunotherapeutics' Shares Outstanding (Weighted Average) stood at $564.6 million in 2021, then jumped by 33.57% to $754.1 million in 2022, then soared by 107.22% to $1.6 billion in 2023, then jumped by 106.41% to $3.2 billion in 2024, then surged by 189.55% to $9.3 billion in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $9.3 billion (Q4 2025), $1.0 (Q2 2025), and $3.2 billion (Q4 2024), per Business Quant data.